je.st
news
Tag: cancer
Pfizer says it could be leader in cancer with many new drugs
2015-09-22 20:12:21| Biotech - Topix.net
Drug giant Pfizer is starting 20 clinical trials this year and more soon after on treatments to conquer cancer as it also seeks to gain leadership in one of the hottest, and most lucrative, areas of medicine. A decade ago, the world's second-biggest drugmaker by revenue wasn't even a player in cancer medicine.
Goldman boss has 'curable' cancer
2015-09-22 14:59:50| BBC News | Business | UK Edition
Goldman Sachs chief executive Lloyd Blankfein announces that he has a "highly curable" form of lymphoma.
Tags: cancer
boss
goldman
curable
Study links California regulations, significant declines in cancer risk from exposure to air toxics
2015-09-22 13:55:31| Green Car Congress
Tags: links
air
study
significant
Data in Nine Difficult-to-Treat Cancers from Mercks KEYTRUDA (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ...
2015-09-21 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. ...Nasopharyngeal Carcinoma, Anal Cancer, Merkel Cell Carcinoma and Biliary Tract Cancer Data to Include First-Time Findings on the Potential Importance of PD-L2 Expression in Predicting Patient Responsiveness to Anti-PD-1 Therapy KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new data investigating the anti-tumor activity of KEYTRUDA (pembrolizumab) across a broad range of advanced cancers will be presented at this years European Cancer Congress (ECC) in Vienna, Austria, Sept. 25-29. In total, 15 KEYTRUDA-related abstracts across nine difficult-to-treat cancers will be presented at this years ECC including four late-breaking oral presentations. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
University Of Copenhagen (UCPH) And Beckman Coulter Genomics Collaborate (BCG) To Unravel How Mutations Rewire Cancer Cells
2015-09-21 03:45:31| drugdiscoveryonline Home Page
Beckman Coulter Genomics, provider of expert sequencing solutions for research and healthcare institutions worldwide, announces the publishing of studies detailing the early results of the strategic collaboration between Beckman Coulter Genomics (BCG) and the Linding Lab at UCPH, Biotech Research & Innovation Centre (BRIC).
Tags: university
cells
cancer
mutations
Sites : [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] next »